ArticleNPJ digital medicine2025
Treatment response-adapted risk index model for survival prediction and adjuvant chemotherapy selection in nonmetastatic nasopharyngeal carcinoma.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)
Who cites it
6 citing papers in PubMed.
- Recent Advances in Surveillance Strategies for Nasopharyngeal Carcinoma.Current oncology reports · 2026Review
- MRI-based assessment of tumor aggressiveness in nasopharyngeal carcinoma: risk stratification and survival prediction.European radiology · 2026Article
- Review
- Diffusion weighted imaging-based tumor growth rate for predicting long-term survival in nasopharyngeal carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Development and validation of a multi-task deep learning model integrating PET-CT radiomics, clinical variables, and EBV DNA for prognostic prediction in locally advanced nasopharyngeal carcinoma.Translational cancer research · 2026Article
- Longitudinal MRI Temporal Transformer Fusion Model for Predicting Induction Chemotherapy Efficacy in Locally Advanced Nasopharyngeal Carcinoma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Dynamic response to therapy is strongly associated with cancer outcomes. We aim to develop the response-adapted individualized risk index (RAIRI) as an individual prognostic approach and predictive biomarker for adjuvant chemotherapy (AC) benefit in nasopharyngeal carcinoma (NPC) based on pretreatment clinical characteristics, longitudinal cell-free Epstein-Barr virus DNA, and MRI-based tumor regression measurements collected during treatment. Using Bayesian joint model, we developed and validated RAIRI, a dynamic and multidimensional model, with 2148 patients in training, internal validation, external validation, and RCT cohorts (ClinicalTrials.gov NCT02958111 2016-11-04 and NCT02143388 2014-05-18). RAIRI predictions were refined over time using serially collected longitudinal data. RAIRI demonstrated accurate calibration and high prognostic accuracy, superior to conventional models. In RCT cohort, RAIRI identified approximately 70% of low-risk patients who did not benefit from AC, whereas the high-risks experienced substantial benefits from AC. Therefore, RAIRI could provide real-time updated quantitative survival estimates for individuals and facilitate personalized AC selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.